Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07047118 · ClinicalTrials.gov registry record · Phase 2
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Phase 2 study of Prostatic Cancer, Castration-Resistant, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 20
- Study locations
NCT07047118 is a Phase 2 study of Prostatic Cancer, Castration-Resistant that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 130 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT07047118, a Phase 2 study of Prostatic Cancer, Castration-Resistant, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
Conditions Studied
Interventions
- DRUG AAA617
- DRUG JSB462
Study Locations (20)
California
- City of Hope National Medical - Duarte
- Providence Saint Johns Health Ctr - Santa Monica
Texas
- Texas Oncology Sammons Cancer Center - Dallas
- Urology San Antonio - San Antonio
Other
- Novartis Investigative Site - Linz
- Novartis Investigative Site - Vienna
Arizona
- Cancer And Blood Spclsts of AZ - Casa Grande
Arkansas
- Highlands Oncology Group - Fayetteville
Colorado
- Rocky Mountain Cancer Centers - Denver
Connecticut
- Yale University School Of Medicine - New Haven
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-07-03 |
| Est. Completion | 2028-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07047118
The ClinicalTrials.gov registry entry for NCT07047118 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Cancer, Castration-Resistant appearing as the primary indexed condition, and to 2 interventions - of which AAA617 is the first listed.
NCT07047118 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT07047118 about?
NCT07047118 is a clinical study titled "A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)". This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Re...
What is the current status of trial NCT07047118?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2025-07-03. Estimated completion is 2028-11-04.
What conditions does trial NCT07047118 study?
This clinical trial studies the following conditions: Prostatic Cancer, Castration-Resistant.
What interventions are being tested in trial NCT07047118?
The interventions under investigation include: AAA617 (DRUG), JSB462 (DRUG).
Who is sponsoring clinical trial NCT07047118?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07047118 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.